Menu Search
Equities

Tevogen Bio Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
G28:FRA

Tevogen Bio Holdings Inc

Actions
  • Price (EUR)0.206
  • Today's Change-0.016 / -7.21%
  • Shares traded100.00
  • 1 Year change-85.99%
  • Beta-0.7603
Data delayed at least 15 minutes, as of Feb 11 2026 08:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

  • Revenue in USD (TTM)0.00
  • Net income in USD-31.42m
  • Incorporated2024
  • Employees18.00
  • Location
    Tevogen Bio Holdings Inc15 Independence Boulevard, Suite #210WARREN 07059United StatesUSA
  • Phone+1 (646) 807-8832
  • Fax+1 (302) 655-5049
  • Websitehttps://tevogen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.